Sentences with phrase «ovarian cancer therapy»

Together, we create an individualized treatment plan that incorporates the latest knowledge in ovarian cancer therapy, both in the operating room and beyond.

Scientists at Lawson Health Research Institute have uncovered an important new target for ovarian cancer therapy.

Not exact matches

Niraparib is closer than any other PARP inhibitor to receiving regulatory approval for ovarian cancer maintenance therapy.

Additionally, women who have received hormone therapy may have an increased risk of ovarian cancer.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

Three trials are now open for OMP - 54F28 (FZD8 - Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, being offered at the CU Cancer Center and elsewhere.

Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the immune system to attack cancer cells as the foreign invaders they are — has so far had limited success, primarily because the immune system often can't destroy the cancer cells.

«Considering that frequent amplification of MET accounts for resistance to therapies now in development and to poor prognosis, not only in ovarian cancer but in other cancers too, our findings pinpoint an important new signaling hub, involving the role of FER in MET activation.

«However, additional research is needed to further evaluate the therapy for this type of ovarian cancer.»

Cancer researcher Janet Sawicki of the Lankenau Institute for Medical Research in Pennsylvania, chemical engineer Robert Langer of MIT, and their colleagues are investigating biodegradable nanoparticles to deliver gene therapy for ovarian cCancer researcher Janet Sawicki of the Lankenau Institute for Medical Research in Pennsylvania, chemical engineer Robert Langer of MIT, and their colleagues are investigating biodegradable nanoparticles to deliver gene therapy for ovarian cancercancer.

This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.

«Combination therapy may be more effective against the most common ovarian cancer.»

Combining chemotherapy and birinapant significantly improved disease - free survival in laboratory models of human ovarian cancer compared to using either therapy alone.

These findings identify specific BRCA1 mutations that are more likely to develop therapy resistance, which may lead to more accurate predictions and personalized treatments for breast and ovarian cancers.

As recent data suggest, PSMA is an important cancer antigen expressed on many human prostate, bladder, renal as well as ovarian cancers, so additional study of the possible benefits of this therapy are important.»

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago today.

The ENGOT - OV16 / NOVA trial evaluated the efficacy and safety of the PARP inhibitor niraparib as maintenance therapy in patients with recurrent ovarian cancer who respond to platinum - based chemotherapy.

Based on these results, two phase 3 trials are being planned for platinum - sensitive and platinum - resistant ovarian cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).

«The findings of this study are exciting because they support the idea that combining these two targeted oral therapies results in significant activity in ovarian cancer, more so than olaparib alone,» said Joyce Liu, M.D., MPH, the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana - Farber Cancer Institute, Bcancer, more so than olaparib alone,» said Joyce Liu, M.D., MPH, the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana - Farber Cancer Institute, BCancer Institute, Boston.

Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.»

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study.

Our approach is to study more than one or two serial recurrences of the disease, adding information about the response to therapy and natural progress of ovarian cancer,» adds J. Brian Szender, MD, MS, senior author and a fellow in Gynecologic Oncology at RPCI.

Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thCancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thcancer is likely to respond to checkpoint inhibitor therapy.

There, in a quest to develop targeted therapies for ovarian cancer, she began studying necroptosis, a form of programmed cell death.

Epigenetic potentiation of NY - ESO - 1 vaccine therapy in human ovarian cancer.

Most of these therapies are still in early - phase testing (phase I and II) for ovarian cancer, but their successful use in other types of cancers suggests that they may ultimately prove useful for ovarian cancer as well.

The poor survival in advanced ovarian cancer is due both to late diagnosis, as well as to the lack of effective second - line therapy for patients who relapse.

The targeted antibody bevacizumab (Avastin ®) is already approved for ovarian cancer patients, and a number of immune - based therapies are being investigated in early - phase clinical trials for patients with ovarian cancer.

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin - paclitaxel therapy.

This raises the exciting possibility that therapies for ovarian cancer might benefit patients with Basal breast tumors, and vice-versa.

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

«This study demonstrates proof of principle for the concept of maintenance therapy in ovarian cancer using a PARP inhibitor.

It becomes standard therapy for the treatment of ovarian cancer and shows promise in lung and breast cancer therapy.

c. Epigenetic approaches to primer for and / or synergize with immunological therapy in epithelial ovarian cancer.

Her long - term goal is to combine conventional and immune therapies in ovarian cancer in order to permit disease control by the immune system, with decreased toxicity and increased survival.

Using state - of - the - art proteomics and associated computational methods, the Speicher laboratory is investigating protein changes associated with ovarian cancer, melanoma, cardiac injury resulting from breast cancer therapies, ectopic pregnancy, red cell diseases, and other clinical disorders.

Tags: checkpoint inhibitors, Clinical Research, immunotherapy, Lung Cancer, McGarry Houghton, Ovarian Cancer, pembrolizumab, Philip D Greenberg, solid tumors, T cell, t cell therapy, Transplant and Immunotherapy

Overholser and colleagues discuss the role of endocrine therapy to reduce risk for breast cancer, and cite interesting data from patients who developed premature ovarian failure due to ovarian irradiation or alkylating chemotherapeutic agents, which demonstrates that these patients were at decreased risk for developing subsequent breast cancer.

A UNC - led study has shown the potential for nanotechnology therapy for ovarian cancer.

The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Both the ovarian and prostate cancer trials could change clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting radiation therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Vaginal estrogen therapy may also be used in women who have breast, cervical or ovarian cancer, and medical consultation must be sought for proper advice on its risks and benefits.

Hormones and Ovarian Cancer Should users of bioidentical hormones be worried about new research showing that all types of estrogen and estrogen plus progestin hormone therapy increase the risk of ovarian Ovarian Cancer Should users of bioidentical hormones be worried about new research showing that all types of estrogen and estrogen plus progestin hormone therapy increase the risk of ovarian cCancer Should users of bioidentical hormones be worried about new research showing that all types of estrogen and estrogen plus progestin hormone therapy increase the risk of ovarian ovarian cancercancer?

Team effort in retrospective Ovarian Cancer Clinical Trial for Targeted Therapies.